Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M. Nielsen Hobbs

M. Nielsen Hobbs has more than 20 years of experience covering the pharmaceutical industry, and writes frequently about the intersection of business, regulation, science and politics. Before joining the “The Pink Sheet” he worked for Congressional Quarterly. Hobbs enjoys discussing BB-8 almost as much as he enjoys talking about 351(k).
Advertisement
Set Alert for Articles By M. Nielsen Hobbs

Latest From M. Nielsen Hobbs

How Drug Promotion Might Change Under Trump's Rx Pricing Plan

DTC disclosure requirements are shiny but probably not substantive; copay navigator might be weightier.

Pricing Debate Advertising, Marketing & Sales

Right-To-Try Bill In House Limits Process To Patients Facing 'Severely Premature Death'

Vote slated for Tuesday; legislation is somewhat narrower than Senate-passed bill, which applies to patients with a 'life-threatening disease or condition.'

Legislation Clinical Trials

Zinbryta Global Withdrawal Driven In Part By Difficulty Of Safety Assessment

EMA safety investigation pushes decision as AbbVie, Biogen acknowledge 'characterizing the evolving benefit/risk profile … will not be possible going forward given the limited number of patients being treated.'

Drug Safety Neurology

Eggs May Be Culprit In Poor Flu Vaccine Performance This Year

US health authorities, manufacturers investigating why egg-based product appears to have lower effect in adults compared to cell-based flu vaccine.

Vaccines Manufacturing

US FDA's Abram Makes The Case For 180-Day Exclusivity Reform

Proposed trigger changes will discourage low-quality applications, not disincentivize patent challenges, deputy commissioner suggests at generic association's annual meeting.

Generic Drugs Legislation

At US Generic Association Annual Meeting, Worries About Sustainability

ANDA sponsors fret price erosion – and potential changes to 180-day exclusivity.
Pricing Debate Generic Drugs
See All
Advertisement
UsernamePublicRestriction

Register